{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=74", "query": { "intervention": "combined therapy treatment", "page": 74 }, "page_size": 10 }, "pagination": { "page": 74, "page_size": 10, "total_count": 12551, "total_pages": 1256, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=75&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=73&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T15:45:21.817Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00863265", "title": "Phytosterols, Ezetimibe, and Cholesterol Metabolism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hypercholesterolemia", "Coronary Heart Disease" ], "interventions": [ { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Phytosterols + ezetimibe", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 22, "start_date": "2009-06", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2018-06-01", "last_synced_at": "2026-11-02T15:45:21.817Z", "location_count": 1, "location_summary": "Logan, Utah", "locations": [ { "city": "Logan", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00863265" }, { "nct_id": "NCT03704714", "title": "Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Aggressive Non-Hodgkin Lymphoma", "B-Cell Non-Hodgkin Lymphoma", "CD20 Positive", "Diffuse Large B-Cell Lymphoma Unclassifiable", "Intravascular Large B-Cell Lymphoma", "Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2018-11-20", "completion_date": "2025-06-11", "has_results": false, "last_update_posted_date": "2022-08-15", "last_synced_at": "2026-11-02T15:45:21.817Z", "location_count": 4, "location_summary": "Chicago, Illinois • Lake Forest, Illinois • Warrenville, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lake Forest", "state": "Illinois" }, { "city": "Warrenville", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03704714" }, { "nct_id": "NCT03441984", "title": "To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Treatment A", "type": "DRUG" }, { "name": "Treatment B", "type": "DRUG" }, { "name": "Treatment C", "type": "DRUG" }, { "name": "Treatment D", "type": "DRUG" }, { "name": "Treatment E", "type": "DRUG" }, { "name": "Treatment F", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 36, "start_date": "2018-02-26", "completion_date": "2018-04-28", "has_results": true, "last_update_posted_date": "2019-12-09", "last_synced_at": "2026-11-02T15:45:21.817Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03441984" }, { "nct_id": "NCT05822752", "title": "Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Budigalimab", "type": "DRUG" }, { "name": "Livmoniplimab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2023-09-21", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-11-02T15:45:21.817Z", "location_count": 20, "location_summary": "Prescott Valley, Arizona • Springdale, Arkansas • Los Angeles, California + 15 more", "locations": [ { "city": "Prescott Valley", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05822752" }, { "nct_id": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Colorectal Cancer", "Breast Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Head and Neck Cancer", "GastroEsophageal Cancer" ], "interventions": [ { "name": "FT536", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Avelumab", "type": "COMBINATION_PRODUCT" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Nivolumab", "type": "COMBINATION_PRODUCT" }, { "name": "Atezolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Trastuzumab", "type": "COMBINATION_PRODUCT" }, { "name": "Cetuximab", "type": "COMBINATION_PRODUCT" }, { "name": "Amivantamab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2022-05-31", "completion_date": "2023-08-11", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-11-02T15:45:21.817Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05395052" }, { "nct_id": "NCT00806234", "title": "Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psychotic Disorders" ], "interventions": [ { "name": "Aripiprazole or Perphenazine", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "19 Years", "sex": "ALL", "summary": "8 Years to 19 Years" }, "enrollment_count": 127, "start_date": "2009-01", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2017-04-25", "last_synced_at": "2026-11-02T15:45:21.817Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Glen Oaks, New York • Chapel Hill, North Carolina", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Glen Oaks", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00806234" }, { "nct_id": "NCT04372433", "title": "IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML With Monocytic Differentiation", "CMML" ], "interventions": [ { "name": "IO-202", "type": "BIOLOGICAL" }, { "name": "IO-202 and Azacitidine", "type": "BIOLOGICAL" }, { "name": "IO-202 and Azacitidine + Venetoclax", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Immune-Onc Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2020-09-14", "completion_date": "2025-01-31", "has_results": false, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-11-02T15:45:21.817Z", "location_count": 14, "location_summary": "Davis, California • Duarte, California • Irvine, California + 11 more", "locations": [ { "city": "Davis", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04372433" }, { "nct_id": "NCT03095352", "title": "Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Chest Wall Disease" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Laura Huppert, MD, BA", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2017-09-02", "completion_date": "2024-11-30", "has_results": true, "last_update_posted_date": "2025-12-22", "last_synced_at": "2026-11-02T15:45:21.817Z", "location_count": 7, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03095352" }, { "nct_id": "NCT07485647", "title": "Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab and Recombinant Human Hyaluronidase", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eden Biltibo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 50, "start_date": "2026-04-20", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-11-02T15:45:21.817Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07485647" }, { "nct_id": "NCT00132158", "title": "ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Rhabdomyosarcomas", "Neuroblastoma", "Osteosarcoma" ], "interventions": [ { "name": "Irinotecan (Camptosar), Gefitinib (Iressa)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 19, "start_date": "2005-09", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2012-04-17", "last_synced_at": "2026-11-02T15:45:21.817Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00132158" } ] }